TWI302533B - N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] caroboxamide inhibitors of cyclin dependent kinases - Google Patents

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] caroboxamide inhibitors of cyclin dependent kinases Download PDF

Info

Publication number
TWI302533B
TWI302533B TW090111741A TW90111741A TWI302533B TW I302533 B TWI302533 B TW I302533B TW 090111741 A TW090111741 A TW 090111741A TW 90111741 A TW90111741 A TW 90111741A TW I302533 B TWI302533 B TW I302533B
Authority
TW
Taiwan
Prior art keywords
methyl
compound
oxazolyl
thio
dimethylethyl
Prior art date
Application number
TW090111741A
Other languages
English (en)
Chinese (zh)
Inventor
Raj Narain Misra
Hai-Yun Xiao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of TWI302533B publication Critical patent/TWI302533B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW090111741A 2000-07-26 2001-05-16 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] caroboxamide inhibitors of cyclin dependent kinases TWI302533B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles

Publications (1)

Publication Number Publication Date
TWI302533B true TWI302533B (en) 2008-11-01

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090111741A TWI302533B (en) 2000-07-26 2001-05-16 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] caroboxamide inhibitors of cyclin dependent kinases

Country Status (26)

Country Link
EP (1) EP1303513A1 (no)
JP (1) JP2004509857A (no)
KR (1) KR20030016429A (no)
CN (1) CN100457753C (no)
AR (1) AR030563A1 (no)
AU (1) AU2001259704A1 (no)
BG (1) BG65132B1 (no)
BR (1) BR0112674A (no)
CA (1) CA2417254A1 (no)
CZ (1) CZ2003237A3 (no)
EE (1) EE200300041A (no)
EG (1) EG24409A (no)
GE (1) GEP20043367B (no)
HR (1) HRP20030116A2 (no)
HU (1) HUP0303698A2 (no)
IL (2) IL153591A0 (no)
LV (1) LV13037B (no)
MX (1) MXPA03000774A (no)
MY (1) MY129635A (no)
NO (1) NO20030394L (no)
PL (1) PL365170A1 (no)
SI (1) SI21099A (no)
SK (1) SK18392002A3 (no)
TW (1) TWI302533B (no)
WO (1) WO2002010162A1 (no)
YU (1) YU4903A (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AR041137A1 (es) 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
AU2003265901B2 (en) 2002-09-04 2006-09-14 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026310A1 (en) 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
DE60317353T2 (de) 2002-09-23 2008-08-28 Schering Corp. Imidazopyrazine als cdk-inhibitoren
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
CA2619790A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
ATE478852T1 (de) 2005-09-09 2010-09-15 Schering Corp Neue 4-cyano-, 4-amino-, und 4- aminomethylderivative von pyrazoloä1,5- aüpyridinen, pyrazoloä1,5-cüpyrimidinen und 2h- indazolverbindungen und 5-cyano-, 5-amino- und 5- aminomethylderivative von imidazoä1,2-aüpyridinen,und imidazoä1,5-aüpyrazinverbindungen als inhibitoren der cyclinabhänggen kinase
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
JP2009539846A (ja) * 2006-06-06 2009-11-19 ブリストル−ミエルス スクイッブ カンパニー Ｎ−［５−［［［５−（１，１−ジメチルエチル）−２−オキサゾリル］メチル］チオ］−２−チアゾリル］−４−ピペリジンカルボキサミドの結晶形
WO2008054749A1 (en) 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2668210C (en) 2006-10-31 2013-03-12 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
BRPI0823416A2 (pt) 2007-05-08 2015-06-16 Schering Corp Métodos de tratamento usando formulações intravenosas compreendendo temozolomida.
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
US8669259B2 (en) 2009-08-26 2014-03-11 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
WO2013148775A1 (en) 2012-03-30 2013-10-03 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
WO2015081867A1 (zh) * 2013-12-04 2015-06-11 杭州民生药物研究院有限公司 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) * 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
AR030563A1 (es) 2003-08-27
CA2417254A1 (en) 2002-02-07
CN1444584A (zh) 2003-09-24
NO20030394L (no) 2003-03-03
GEP20043367B (en) 2004-06-10
MY129635A (en) 2007-04-30
AU2001259704A1 (en) 2002-02-13
WO2002010162A1 (en) 2002-02-07
CZ2003237A3 (cs) 2003-06-18
EE200300041A (et) 2005-04-15
JP2004509857A (ja) 2004-04-02
EP1303513A1 (en) 2003-04-23
LV13037B (en) 2003-11-20
NO20030394D0 (no) 2003-01-24
PL365170A1 (en) 2004-12-27
IL153591A (en) 2009-07-20
BR0112674A (pt) 2003-12-30
CN100457753C (zh) 2009-02-04
BG65132B1 (bg) 2007-03-30
HUP0303698A2 (hu) 2004-04-28
SI21099A (sl) 2003-06-30
BG107468A (en) 2004-01-30
KR20030016429A (ko) 2003-02-26
MXPA03000774A (es) 2003-09-10
EG24409A (en) 2009-05-20
SK18392002A3 (sk) 2003-09-11
IL153591A0 (en) 2003-07-06
HRP20030116A2 (en) 2005-02-28
YU4903A (sh) 2006-03-03

Similar Documents

Publication Publication Date Title
TWI302533B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] caroboxamide inhibitors of cyclin dependent kinases
US6515004B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
TWI273103B (en) N-[5-[[[5-alkyl-2-oxazolyl methyl]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
ZA200204349B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
US6214852B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
AU730607B2 (en) Aminothiazole inhibitors of cyclin dependent kinases
US10233180B2 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
LT5106B (lt) Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai
ZA200300452B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees